Compare IMNM & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | BCC |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | 7680 |
| Industry | Medicinal Chemicals and Botanical Products | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2020 | 2012 |
| Metric | IMNM | BCC |
|---|---|---|
| Price | $28.01 | $82.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $32.80 | ★ $99.20 |
| AVG Volume (30 Days) | ★ 1.1M | 315.0K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ 2.11 |
| Revenue | $6,941,000.00 | ★ $4,995,290,000.00 |
| Revenue This Year | N/A | $3.41 |
| Revenue Next Year | $1,127.34 | $4.76 |
| P/E Ratio | ★ N/A | $39.09 |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $8.67 | $65.00 |
| 52 Week High | $30.06 | $91.97 |
| Indicator | IMNM | BCC |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 52.78 |
| Support Level | $18.72 | $71.52 |
| Resistance Level | N/A | $87.75 |
| Average True Range (ATR) | 1.51 | 2.34 |
| MACD | 0.15 | -0.48 |
| Stochastic Oscillator | 66.25 | 27.81 |
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.